For research use only. Not for therapeutic Use.
Rosnilimab(CAT: I040849) is an investigational monoclonal antibody designed to target PD-1 (programmed cell death protein 1), a key immune checkpoint receptor involved in immune regulation. By blocking PD-1, Rosnilimab enhances T-cell activation, promoting immune responses against cancer and autoimmune diseases. It is being explored as a potential therapeutic for conditions such as rheumatoid arthritis, psoriasis, and other inflammatory disorders. With its high specificity and potent immunomodulatory effects, Rosnilimab represents a promising candidate for advancing immunotherapy research in oncology and autoimmune disease treatment.
| CAS Number | 2412764-40-8 |
| Purity | ≥95% |
